Table 2.
CMV Disease and Treatment Characteristics
| N (%) | |
|---|---|
| Demographic Characteristic | (N=35) |
| Viremia present | 29 (83%) |
| Maximum CMV PCR titer, median copies/mL (range)a | 145,160 (2000–4.7*106) |
| Duration of viremia, median days (range) | 18 (3–85) |
| CMV Disease | |
| Pneumonitis | 26 (74%) |
| Enteritis | 9 (26%) |
| CMV Pneumonitis (N=26) | |
| Viremia present | 20 (77%) |
| BAL CMV PCR or culture positive | 7 (27%) |
| Intubated | 14 (54%) |
| Treatment prior to intubationb | 11 (79%) |
| Treatment within 24 hours of intubationb | 12 (86%) |
| CMV Enteritis (N=9) | |
| Viremia present | 9 (100%) |
| Histologically-observed inclusion bodies | 7 (78%) |
| Treatment prior to CMV enteritis diagnosis | 6 (67%) |
| Treatment within 24 hours of CMV enteritis diagnosis | 8 (89%) |
| CMV disease diagnosis, median days post-HSCT (range) | 63 (0–369) |
| Total CMV-IVIG doses administered, mean (SD) | 4 (±2.0) |
| CMV-IVIG initiation, median days post-CMV disease diagnosis (range) | 0 (0–15) |
| CMV-IVIG initiation, median days post-viremia (range) | 10 (0–62) |
| Concomitant antivirals administered | |
| Ganciclovir | 31 (89%) |
| Foscarnet | 14 (40%) |
CMV – Cytomegalovirus; PCR – Polymerase chain reaction; BAL – Bronchoalveolar lavage; HSCT – Hematopoietic stem cell transplant; CMV-IVIG – Cytomegalovirus intravenous immune globulin
a
N=15, as this testing method was not available for the full cohort
b
These characteristics were not mutually exclusive